Table 2.
Association of CYP19A1 rs4646 genotypes with disease-free survival
| CYP19A1 polymorphisms | n | HR (95% CI) | P | HR (95% CI)* | P* |
|---|---|---|---|---|---|
| All patients | |||||
| CC | 152 | 1.0 (reference) | 0.106 | 1.0 (reference) | 0.044 |
| AC | 115 | 0.766 (0.570-1.028) | 0.716 (0.528-0.970) | ||
| AA | 20 | 0.641 (0.351-1.170) | 0.585 (0.311-1.099) | ||
| CC/AC | 267 | 1.0 (reference) | 0.266 | 1.0 (reference) | 0.187 |
| AA | 20 | 0.716 (0.396-1.293) | 0.657 (0.352-1.227) | ||
| CC | 152 | 1.0 (reference) | 0.040 | 1.0 (reference) | 0.011 |
| AC/AA | 135 | 0.745 (0.562-0.988) | 0.681(0.506-0.917) | ||
| Premenopausal patients | |||||
| CC | 115 | 1.0 (reference) | 0.026 | 1.0 (reference) | 0.013 |
| AC | 87 | 0.786 (0.566-1.091) | 0.746 (0.533-1.044) | ||
| AA | 15 | 0.384 (0.177-0.834) | 0.323 (0.140-0.741) | ||
| CC/AC | 202 | 1.0 (reference) | 0.024 | 1.0 (reference) | 0.017 |
| AA | 15 | 0.425 (0.198-0.914) | 0.336 (0.160-0.836) | ||
| CC | 115 | 1.0 (reference) | 0.033 | 1.0 (reference) | 0.019 |
| AC/AA | 102 | 0.709 (0.516-0.975) | 0.670 (0.479-0.938) | ||
| Postmenopausal patients | |||||
| CC | 37 | 1.0 (reference) | 0.011 | 1.0 (reference) | 0.015 |
| AC | 28 | 0.681 (0.348-1.334) | 0.517 (0.245-1.091) | ||
| AA | 5 | 3.115 (1.159-8.375) | 2.575 (0.900-7.371) | ||
| CC/AC | 65 | 1.0 (reference) | 0.005 | 1.0 (reference) | 0.013 |
| AA | 5 | 3.613 (1.380-9.457) | 3.614 (1.308-9.991) | ||
| CC | 37 | 1.0 (reference) | 0.648 | 1.0 (reference) | 0.287 |
| AC/AA | 33 | 0.868 (0.473-1.594) | 0.687(0.348-1.354) |
Note: HR, hazard ratio; CI, confidence interval.
*
Adjusted by positive lymph nodes, tumor size >2 cm, negative hormone receptor status, HER-2-postive status, chemotherapy, BMI > 24 in multivariate analyses.